A) Individuals positive for at least 1 E antibody versus individuals negative for those E antibodies (P<.001). <.05 was considered significant, and all checks were 2-sided. Standard descriptive statistical methods were used to describe demographic and medical characteristics. Overall survival was defined as time from first visit to death from any cause. Progression-free survival was defined as time from first visit to clinical detection of recurrent malignancy (local, regional, or distant) or death from GSK2256098 any cause. Participants GSK2256098 alive and recurrence-free (for progression-free survival) at last follow-up or lost to follow-up were regarded as censored. KaplanCMeier curves were created to compare survival between organizations, and the log-rank statistic was used to test the hypothesis of a difference in survival between organizations. Cox proportional risks models were used to determine risk ratios (HRs) and 95% CIs to assess whether presence of specific HPV16 antibodies was associated with overall GSK2256098 and progression-free survival. Akaike info criterion was used to select variables for inclusion in the multivariable models. Overall and progression-free survival within each group of individuals were assessed separately and the models with minimum AIC were used as the final models. Additionally, smoking is definitely a known predictor for survival and was included in the models. A binary logistic regression model was used to compute the area under the receiver operating characteristic curve (ROC) to compare the performance of all mixtures of E antibodies for predicting disease recurrence. The probability cut-off value for the predictions was 0.5. Results A total Mouse monoclonal to CD95(FITC) of 209 individuals were included in the final analysis. Of these, 114 experienced tumor HPV16 status available GSK2256098 for subgroup analyses; 96 of these individuals experienced HPV16-positive tumors. The median follow-up time for individuals who survived was 62.7 months (range, 3.9C96.9 months). The median follow-up time for individuals with HPV16-positive tumors who survived was 68.9 months (range, 4.1C92.5 months). There was no difference with respect to survival between individuals who experienced tumor HPV16 status available and those who did not (P=.577). Demographic and medical characteristics The demographic, exposure, and medical characteristics of the individuals are summarized in Table 1. Ninety percent of individuals were positive for at least 1 E antibody, while 16% were positive for at least 1 L antibody. Of the 114 individuals with tumor HPV16 DNA status available, 96 (84%) experienced HPV16-positive tumors. The characteristics of the individuals by tumor HPV16 status are demonstrated in Table 1. Table 1 Demographic, exposure, and clinical characteristics of 209 individuals with OPCa
Age, imply (SD), years55.8 (9.2)54.8 (8.4)56.7 (8.1)Age, median, years555454Sex lover.429d????Male184 (88.0)86 (89.6)15 (83.3)????Female25 (12.0)10 (10.4)3 (16.7)Race.657d????White colored192 (91.9)88 (91.7)16 (88.9)????Additional17 (8.1)8 (8.3)2 (11.1)Smoking.708d????Never103 (49.3)45 (46.9)10 (55.6)????Past71 (34.0)32 (33.3)4 (22.2)????Current35 (16.8)19 (19.8)4 (22.2)Pack-years of smoking.508????10130 (62.5)56 (58.3)12 (66.7)????>1078 (37.5)40 (41.7)6 (33.3)????Missing100Alcohol use.237d????Never60 (28.7)23 (24.0)5 (27.8)????Past52 (24.9)29 (30.2)2 (11.1)????Current97 (46.4)44 (45.8)11 (61.1)Subsite.039d????Tonsil99 (47.4)43 (44.8)14 (77.8)????Foundation of tongue105 (50.2)49 (51.0)4 (22.2)????Additional oropharynx5 (2.4)4 (4.2)0Stage.095d????I-II17 (8.1)8 (8.3)4 (22.2)????III-IV192 (91.9)88 (91.7)14 (77.8)T category.233d????0C2156 (74.6)70 (72.9)16 (88.9)????3C453 (25.4)26 (27.1)2 (11.1)N category.047????0C2a57 (27.3)30 (31.3)10 (55.6)????2b-3152 GSK2256098 (72.7)66 (68.8)8 (44.4)Grade.392????Well-moderately differentiated61 (33.7)31 (36.1)8 (47.1)????Moderately-poor to poorly differentiated120 (66.3)55 (64.0)9 (52.9)????Missing28101Treatmentb.525????Radiation59 (28.2)30 (31.3)7.